GeoWealth Management LLC acquired a new position in shares of Revvity, Inc. (NYSE:RVTY – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 541 shares of the company’s stock, valued at approximately $60,000.
A number of other institutional investors have also recently bought and sold shares of the company. Assetmark Inc. raised its stake in Revvity by 3,700.0% during the 4th quarter. Assetmark Inc. now owns 266 shares of the company’s stock worth $30,000 after buying an additional 259 shares during the period. Millstone Evans Group LLC acquired a new stake in shares of Revvity during the fourth quarter worth about $38,000. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Revvity by 55.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 385 shares of the company’s stock valued at $43,000 after purchasing an additional 138 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Revvity by 33.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 522 shares of the company’s stock valued at $58,000 after purchasing an additional 131 shares during the period. Finally, Principal Securities Inc. increased its stake in Revvity by 54.9% during the 4th quarter. Principal Securities Inc. now owns 598 shares of the company’s stock worth $67,000 after purchasing an additional 212 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.
Insider Buying and Selling at Revvity
In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total value of $1,922,494.10. Following the transaction, the insider now directly owns 33,400 shares in the company, valued at $4,232,782. The trade was a 31.23 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.68% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on RVTY
Revvity Price Performance
NYSE:RVTY opened at $94.30 on Friday. The stock has a market capitalization of $11.33 billion, a PE ratio of 42.67, a P/E/G ratio of 3.82 and a beta of 1.07. Revvity, Inc. has a 1-year low of $88.53 and a 1-year high of $129.50. The firm has a fifty day simple moving average of $104.87 and a 200 day simple moving average of $113.09. The company has a current ratio of 3.60, a quick ratio of 3.03 and a debt-to-equity ratio of 0.41.
Revvity (NYSE:RVTY – Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the prior year, the firm posted $1.25 earnings per share. On average, research analysts expect that Revvity, Inc. will post 4.94 EPS for the current fiscal year.
Revvity Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity’s dividend payout ratio (DPR) is presently 12.67%.
Revvity Company Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Further Reading
- Five stocks we like better than Revvity
- How to Use the MarketBeat Dividend Calculator
- Short Sellers Gave Up on These 3 Names Recently
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Boring Stocks Outperforming the Market This Year
- How to invest in marijuana stocks in 7 steps
- If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
Want to see what other hedge funds are holding RVTY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revvity, Inc. (NYSE:RVTY – Free Report).
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.